Abstract
A series of N-(5-methyl-isoxazol-3-yl/1,3,4-thiadiazol-2-yl)-4-(3-substitutedphenylureido) benzenesulfonamide derivatives has been designed, synthesized and screened for their in vitro human carbonic anhydrase (hCA; EC 4.2.1.1) inhibition potential. These newly synthesized sulfonamide compounds were assessed against isoforms hCA I, II, VII and XII, with acetazolamide (AAZ) as a reference compound. The majority of these compounds were found quite weak inhibitor against all tested isoforms. Compound 15 showed a modest inhibition potency against hCA I (Ki = 73.7 μM) and hCA VII (Ki = 85.8 μM). Compounds 19 and 25 exhibited hCA II inhibition with Ki values of 96.0 μM and 87.8 μM, respectively. The results of the present study suggest that, although the synthesized derivatives have weak inhibitory potential towards all investigated isoforms, some of them may serve as lead molecules for the further development of selective inhibitors incorporating secondary sulfonamide functionalities, a class of inhibitors for which the inhibition mechanism is poorly understood.
Acknowledgements
The University Science Instrumentation Center (USIC), University of Delhi is acknowledged for providing NMR and Mass spectral characterization of the synthesized compounds.
Declaration of interest
Chandra Bhushan Mishra (DSK-PDF) and Shikha Kumari are thankful to the University Grant Commission for providing financial support. Author Amresh Prakash is thankful to SERB-YSS for financial support. Manisha Tiwari deeply acknowledges the financial support to carry out this research work. Work from Supuran laboratory was financed by two EU grants (Dynano and Metoxia).